the multi-disciplinary team caring for men with mCRPC features a increasing choice of agents to make use of in the article docetaxel setting. The recent and emerging treatments vary widely in their mode of action, and there is no suggestion, up to now, that people is likely to be in a position to benefit from only one of the options. Certainly, the possibility Ganetespib concentration continues to be mooted of mCRPC entering an age of serious illness style management, having an array of treatments, each improving the survival of the individual. 5 Despite the choice narrowed to the 2 agents currently approved to be used post docetaxel, it’s anticipated that patients is likely to be able to obtain a survival benefit from both abiraterone and cabazitaxel. 6 The key issue for their patients and clinicians is, how do these treatments be sequenced to maximise each people survival? This article presents an overview of the Inguinal canal evidence base for the approved and emerging treatments for mCRPC postdocetaxel, and considers how to ensure that suitable people have the ability to enjoy the two treatments currently available. . Emergency post docetaxel, Evidence base Current possibilities Cabazitaxel The rationale for use of cabazitaxel in mCRPC post docetaxel is discussed at length elsewhere by Asselah and Saad within this supplement, page S5. 7 In brief, TROPIC showed that cabazitaxel enhanced median overall survival, and that the advantage applied to all sub-groups analyzed. 3 Interim results in the EAP indicate improvement in pain control with continuous therapy, and stable scores for anxiety/depression, flexibility and self care. 8,9 Abiraterone The decision to analyze abiraterone in mCRPC came from the observation that enzymes involved in androgen synthesis are unregulated in the problem, leading to increased androgen levels in the cyst. 10 Abiraterone acetate blocks cytochrome p-450 c17, an enzyme necessary for testosterone synthesis, early trials of the agent showed promising anti c-Met inhibitor tumor activity in individuals with mCRPC both before and after chemotherapy. . 4 The phase III COU AA 301 trial compared abiraterone 1,000 mg/day plus prednisone 10 mg/day with placebo plus prednisone 10 mg/day in men with mCRPC who’d previously received chemotherapy. 4 COU AA 301 showed that abiraterone enhanced median overall survival, in the research, men in the abiraterone team lasted 15. 8 months, in contrast to 11. 2 months in the placebo group. 11 Moreover, the initial test survey indicated the survival advantage applied to all subgroups analyzed. Since the trials differed in various parameters, 4 COU and TROPIC AA 301, crucial differences in trial design It’s improper to attract direct comparisons between COU AA 301 and TROPIC. Rising options Phase III data are available on the following 3 agents, each showing a survival benefit in patients with mCRPC. None of these treatments are approved for use in Canada.